COVID-19

Developments

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates and FastPharming manufacturing system were featured on The Hill’s coronavirus report on July 30. The company is developing IBIO-200 and IBIO-201, virus-like...

July 30, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Developments

PhaseBio doses first COVID-19 patient in Phase 2 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) dosed the first patient in its potentially pivotal Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of...

July 17, 2020

Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020

Developments

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Rigel Pharmaceuticals’ (NASDAQ:RIGL) fostamatinib is being evaluated in an investigator-sponsored study for the treatment of COVID-19 pneumonia. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is approved...

July 14, 2020

Developments

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

Akebia Therapeutics’ (NASDAQ:AKBA) vadadustat is being evaluated in an investigator-sponsored study as a potential therapy to prevent and lessen the severity of COVID-19-related acute respiratory distress syndrome...

July 14, 2020

Developments

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is an orally...

July 13, 2020

Developments

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

Bellerophon Therapeutics (NASDAQ:BLPH) treated the first patient in its Phase 3 study evaluating INOpulse, a pulsed nitric oxide system, for the treatment of COVID-19. The study will enroll up to 500 patients requiring...

July 13, 2020

Developments

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

The FDA has issued an emergency use authorization for electroCore’s (NASDAQ:ECOR) gammaCore Sapphire CV non-invasive vagus nerve stimulation (nVNS) to treat adult patients with known or suspected COVID-19. The FDA has...

July 13, 2020

Tag - COVID-19

The Hill’s coronavirus report features iBio COVID-19 vaccine candidates and FastPharming System

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Cerecor enrolls first patient in COVID-19 trial

PhaseBio doses first COVID-19 patient in Phase 2 trial

HCW ups electroCore PT to $2.50 from $1.50

Rigel Pharma fostamatinib being evaluated in COVID-19 pneumonia trial

Akebia vadadustat being evaluated for COVID-19-related acute respiratory distress syndrome

BioSig subsidiary begins enrollment in Phase 2 COVID-19 trial

Bellerophon treats first COVID-19 patient in Phase 3 INOpulse study

FDA authorizes emergency use of electroCore’s vagus nerve stimulation in COVID-19 patients

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter